Leishmaniavirus genetic diversity is not related to leishmaniasis treatment failure

Autor: Sébastien Briolant, Marine Ginouves, Eliane Bourreau, Magalie Demar, Paul Brousse, S. Simon, S. Rogier, P. Travers, V. Pommier de Santi, Pierre Couppié, Ghislaine Prévot
Přispěvatelé: Ecosystemes Amazoniens et Pathologie Tropicale (EPat), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Guyane (UG), Centre National de Référence Leishmania [Cayenne, Guyanne Française] (Laboratoire Associé), Laboratoire Hospitalo-Universitaire de Parasitologie-Mycologie, Coordination Régionale de la lutte contre le Virus de L'Immunodéficience Humaine (COREVIH)-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]-Université des Antilles (UA)-Coordination Régionale de la lutte contre le Virus de L'Immunodéficience Humaine (COREVIH)-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]-Université des Antilles (UA), Service de Dermatologie et Vénérologie [CH de Cayenne, France], Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Institut Pasteur de la Guyane, Réseau International des Instituts Pasteur (RIIP), Centre d'Investigation Clinique Antilles-Guyane (CIC - Antilles Guyane), Université des Antilles et de la Guyane (UAG)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de Fort de France-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Département des Centres Délocalisés de Prévention et de Soins [Cayenne, Guyane Française], Pôle des Centres Délocalisés de Prévention et de Soins [CH Andrée Rosemon, Guyane Française], Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), Coordination Régionale de la lutte contre le Virus de L'Immunodéficience Humaine (COREVIH)-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]-Université des Antilles (UA), This work was supported by the University of French Guiana and the Ministère Français de l'Enseignement Supérieur et de la Recherche Scientifique., This work has benefited from an 'Investissement d’Avenir' grant managed by Agence Nationale de la Recherche (CEBA, ref. ANR-10-LABX-25-01)., We thank all trainees who participated in this project at the level of experimental work (Claudiane FLORAT, Yasmine AUGUSTE, Ruthly JEAN-BAPTISTE, Keïta BAGADI, Kévin JOSEPH). We also thank all CHC staff (Audrey Ambouille, Géraldine Gangasing, Philippe Travers, Basma Guarmit, Céline Michaud) and health centers staff (Maripasoula: Christelle Maabo, Wilmina Alfred, Melaine Boce and their colleagues, Papaichton: Naïka Amayota and colleagues, in Cacao: Malika Miquel and colleagues, in Saint Georges: Eric Crougneau and colleagues, in Apatou: Pauline Alifons and colleagues, in Saül: Séverine and colleagues, in Trois sauts: Benoit Quentin, Laure Gerold and colleagues) who helped us to carry out this project. We thank Antoine Adenis for his help in the sensitivity study. We thank reviewers and editor for their advice., ANR-10-LABX-0025,CEBA,CEnter of the study of Biodiversity in Amazonia(2010), CCSD, Accord Elsevier, Laboratoires d'excellence - CEnter of the study of Biodiversity in Amazonia - - CEBA2010 - ANR-10-LABX-0025 - LABX - VALID, Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA)
Rok vydání: 2021
Předmět:
Male
Genotyping Techniques
genotype
Gastroenterology
Group B
0302 clinical medicine
[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases
Genotype
Leishmaniavirus
Leishmania guyanensis
Phylogeny
LRV1
[SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology
[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases
[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases
0303 health sciences
biology
General Medicine
French Guiana
[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
3. Good health
Infectious Diseases
[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology
[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases
Female
[SDV.MP.PAR] Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology
medicine.drug
Adult
Microbiology (medical)
medicine.medical_specialty
030231 tropical medicine
Leishmaniasis
Cutaneous
Virus
Young Adult
03 medical and health sciences
[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
pentamidine
Internal medicine
medicine
Humans
[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology
Retrospective Studies
treatment failure
030304 developmental biology
Sequence Analysis
RNA
business.industry
Genetic Variation
Leishmaniasis
medicine.disease
Leishmania
biology.organism_classification
[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology
[SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology
business
Pentamidine
Zdroj: Clinical Microbiology and Infection
Clinical Microbiology and Infection, 2020, pp.S1198-743X(20)30265-2. ⟨10.1016/j.cmi.2020.04.037⟩
Clinical Microbiology and Infection, Elsevier for the European Society of Clinical Microbiology and Infectious Diseases, 2020, pp.S1198-743X(20)30265-2. ⟨10.1016/j.cmi.2020.04.037⟩
ISSN: 1198-743X
1469-0691
Popis: Objectives The outcome of American tegumentary leishmaniasis (ATL) may depend on the presence of the Leishmania RNA virus (LRV). This virus may be involved in treatment failure. We aimed to determine whether genetic clusters of LRV1 are involved in this therapeutic outcome. Methods The presence of LRV1 was assessed in 129 Leishmania guyanensis isolates from patients treated with pentamidine in French Guiana. Among the 115 (89%) isolates found to carry LRV1, 96 were successfully genotyped. Patient clinical data were linked to the LRV data. Results The rate of treatment failure for LRV1-positive isolates was 37% (15/41) versus 40% (2/5) among LRV1-negative isolates (p 0.88). Concerning LRV1 genotypes, two predominant LRV1 groups emerged, groups A (23% (22/96)) and B (70% (67/96)). The treatment failure rate was 37% (3/8) for group A and 45% (9/20) for group B (p 0.31). Discussion Neither the presence nor genotype of LRV1 in patients with L. guyanensis seemed to correlate with pentamidine treatment failure.
Databáze: OpenAIRE
Externí odkaz: